Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan

Anne M. Ireland, DNP, RN, AOCN®, CENP
Voice

Description

After clinical trial results demonstrated a four-month improvement in overall survival compared to best standard care, in March 2022 the U.S. Food and Drug Administration approved lutetium lu 177 vipivotide tetraxetan (PluvictoTM) to treat prostate-specific membrane antigen (PSMA)–expressing metastatic castration-resistant prostate cancer (mCRPC).

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Related Topics